I have one last point. How do you see that working group and the importance of that working group with our partners on biotech? I've heard from many stakeholders about the trade irritants that develop from that. Do you see that as a good body and a good vehicle to deal with those particular issues, or is it “We'll see”?
On February 20th, 2020. See this statement in context.